• Grey Facebook Icon
  • Grey Twitter Icon
  • Grey LinkedIn Icon

2020

 

  • Zorea J.  Shakula R.,  Elkabets M., Ben-Yoav  H. Probing antibody surface density and analyte antigen incubation time as dominant parameters influencing the antibody-antigen recognition events of a non-faradaic and diffusion-restricted electrochemical immunosensor. Analytical and Bioanalytical Chemistry. PDF

  • Prasad M.  Jagadeeshan S.,  Scaltriti M., Allon I., Elkabets E. In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System. JoVE PDF

  • Azulay E. Cooks T. Elkabets M. Potential oncogenic roles of mutant-p53-derived exosomes in the tumor-host interaction of head and neck cancers. Cancer Immunology and Immunotherapy PDF

 

2019

  • Jagadeeshan S, Prasad M, Ortiz-Cuaran S., Gregoire V, Saintigny P., Elkabets M.. Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. Trends In Cancer May 2019 - PDF

  • Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, Yossef R, Shemesh A, Soria JC, Lazar V, Joshua BZ, Campbell KS, Elkabets M, Porgador A. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA. Cancer Immunotherapy Research Jul 2019

  • Boichuck M, Zorea J, Elkabets M, Wolfson M, Fraifeld VE. c-Met as a new marker of cellular senescence. Aging May 2019

  • Varon M, Levy T, Mazor G, Ben David H, Marciano R, Krelin Y, Prasad M, Elkabets M, Pauck D, Ahmadov U, Picard D, Qin N, Borkhardt A, Reifenberger G, Leprivier G, Remke M, Rotblat B. The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells. International Journal of Cancer May 2019

  • Badarni M, Prasad M, Balaban N, Zorea J, Yegodayev KM, Joshua BZ, Bahat Dinur A, Grénman R, Rotblat B, Cohen L, Elkabets M. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI Insight March 2019 - PDF

  • Marziano R, Parsad M,  Levy T, Tzadok S, Lepivier G, Elkabets M, Rotblat B. High-Throughput Screening Identified Compounds Sensitizing Tumor Cells to Glucose Starvation in Culture and VEGF Inhibitors In Vivo- Cancers Jan 2019 - PDF

  • Novoplansky O, Fury M, Prasad M, Yegodayev K, Zorea J, Cohen L, Pelossof R, Cohen L, Katabi N, Cecchi F, Joshua BZ, Popovtzer A, Baselga J, Scaltriti M, Elkabets M.  MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.- International Journal of Cancer Jan 2019 - PDF

  • Ghosh S, Prasad M, Kundu K, Cohen L, Yegodayev KM, Zorea J, Joshua BZ, Lasry B, Dimitstein O, Bahat-Dinur A, Mizrachi A, Lazar V, Elkabets M*‡ and Porgador A. Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy. Frontiers Oncology Jan 2019  PDF

  • Ben-Aharon I, Elkabets M., Pelossof R, H. Yu K., Iacubuzio CA., Donahue,  Leach SD, Lowery MA., O'Reilly EM. Genomic Landscape of Pancreatic Adenocarcinoma in Younger vs Older Patients: Does Age Matter?. Clinical Cancer Research Jan 2019 PDF

2018

  • Zorea J, Prasad M, Cohen L, Li N, Schefzik R, Ghosh S, Rotblat B, Brors B, Elkabets M.IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer. Cell Death Dis. PDF

  • Elkabets M, Brook S. Methods to Study the Role of Progranulin in the Tumor Microenvironment. Methods Mol Biol. 

2017

  • Toska E., Osmanbeyoglu H., Castel P., Chan C., Hendrickson R.C, Elkabets M., Dickler M., Scaltriti M., Leslie C.S, Armstrong S.A, Baselga J.. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science March 2017

2016

  • Shamay Y., Elkabets M., Hongyan Li, Shah J.,Brook S., Wang F.,  AdlerK., Baut E.,   Scaltriti M.,  Prakrit V. Jena,Gardner EE.,  Poirier, Jp., Rudin CM., Baselga J., Haimovitz-Friedman A.,Heller D.A. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med 2016 July PDF

  • Scaltriti M., Elkabets M.,  Baselga J. Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clin Cancer Res. 2016 Jan 13.   PDF 

 2015

  • Elkabets M., Pazarentzos E., Sheng Q., Pelossof R.A., Brook S., Morse N., Yan JJ., Liu M., Das R., Chen Y., Tam A., Wang H., Liang J., Huang A., Ghissein RA., Rosen N., Bivona T.G., Scaltriti M., Baselga J. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015   PDFF

 

2014

  • Castel P., Toska E., Zumsteg Z., Carmona J., Elkabets M., Bosch A, Scaltriti M. Rationale-based therapeutic combinations with PI3K inhibitors in cancer. Molecular & Cellular Oncology 2014 Oct   PDF

 

  • Tao J., Castel P., Radosevic-Robin N., Elkabets M., Auricchio N., Aceto N., Weitsman G., Barber P., Vojnovic B., Ellis H., Morse N., Viola-Villegas NT., Campos AB., Juric D., Hazra H., Singh S., Kim P., Bergamaschi A., Maheswaran S., Ng T., Penault-Llorca F., Lewis JS., Carey LA., Perou CM., Baselga J., Scaltriti M. Sci. Signal 2014 Mar  PDF

 

​2013

  • Elkabets M.*, Vora S.*, Juric D., Morse N., Mino-Kenudson M., Muranen T., Tao J., Campos AB., Rodon J., Ibrahim YH., Serra V., Rodrik-Outmezguine V., Hazra S., Singh S., Kim P., Quadt C., Liu M., Huang A., Rosen N., Engelman JA., Scaltriti M., Baselga J. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013 Jul.  *Equal Contribution.  PDF

 

  • Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, Rider P, Idan Cohen, Romzova M, Kaplanov I, Apte RN. Unique Versus Redundent Dunctions of IL-1a and IL-1b in the tumor microenvironment. Front Immunol 2013 Jul

 

2011

  • Elhaik-Goldman S., Kafka D., Yossef R., Hadad U., Elkabets M, Vallon-Eberhard A., Hulihel L., Jung S., Ghadially H., Apte RN., Mandelboim O., Dagan R., Mizrachi-Nebenzahl Y., Porgador A. The Natural Cytotoxicity Receptor 1 Contribution to Early Clearance of Streptococcus Pneumoniae and to Natural Killer-Macrophage Cross Talk. PLoS One 2011 Aug.

 

  • Carmi Y., Rinot G., Elkabets M., Dotan S., Voronov E., Apte RN. Microenvironment-derived IL-1 and IL-17 interact in regulation of invasiveness of lung metastasis. J Immunol 2011 Feb.

 

  • Elkabets M.*, Gifford AG.*, Scheel C., Nilsson B., Reinhardt F., Bray MA., Carpenter AE., Jirström K., Magnuson K., Ebert BL., Pontén F.,. Weinberg RA., McAllister SS. Human Tumors Instigate Granulin-Expressing Hematopoietic Cells that Promote Malignancy by Activating Stromal Fibroblasts in Mice. J Clin Invest. 2011 Feb *Equal Contribution.  PDF

 

2010

  • Elkabets M., Gomes-Ribeiro V, Dinarello CA., Ostrand-Rosenberg S, Di Santo JP, Apte RN,. Vosshenrich C.A. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J immunol 2010 Dec.  PDF

 

  • Cohen M*, Elkabets M.*, Perlmutter M. Voronov E.. Apte R.N. and Lichtenstein RG. Sialylation of 3- Methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting. J Immunol 2010 Oct 18 *Equal Contribution.  PDF

 

  • Sarfati G., Dvir T., Elkabets M., Apte RN., Cohen S. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials 2010 Oct13.  

 

  • Voronov E., Dotan S., Gayvoronsky L., White RM., Cohen I., Benchetrit F., Elkabets M., Huszar M., Fogel M., El-On J., and Apte RN . IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. Int Immunol. 2010 Apr 22.

 

2009

  • Avidan A., Perlmutter M., Tal S., Oraki O., Kapp T., Krelin Y., Elkabets M., Dotan S., Apte RN., Lichtenstein RG. Differences in the sialylation patterns of membrane stress proteins in chemical carcinogen-induced tumors developed in BALB/c and IL-1alpha deficient mice. Glycoconj J. 2009 Dec 26

 

  • Elkabets M., Krelin Y., Dotan S., Cerwenka A., Porgador A., Lichtenstein G.R., Dinarello CA., White R.W., Zoller M., Voronov E., and Apte RN. Host-derived Interleukin-1α is important in determining The immunogenicity of 3-Methylcholantrene-tumor cells. J Immunol 2009 Apr 15.  PDF

 

2007

  • Krelin Y., Voronov E., Dotan S., Elkabets M., Reich E., Fogel M., Huszar M., Iwakura Y., Segal S., Dinarello CA., Apte RN. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007 Feb.

 

  • Apte RN., Dotan S., Elkabets M., White MR., Reich E., Carmi Y., Song X., Dvozkin T., Krelin Y., Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep 25(3):387-408

 

  • Apte RN., Krelin Y., Song X., Dotan S., Recih E., Elkabets M., Carmi Y., Dvorkin T., White RM., Gayvoronsky L., Segal S., Voronov E. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer. 2006 Apr 42(6):751-9

 

  • Leizerman I., Avunie-Masala R., Elkabets M., Fich A., Gheber L. Differential effects of monastrol in two human cell lines. Cell Mol Life Sci. 2004 Aug 61(16):2060-70.

Publications